(Q38662743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

review article

1 reference

title

Targeted radionuclide therapy in combined-modality regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Katherine A Vallis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Nadia Falzone

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Yong Du

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

publication date

1 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

24 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

e414-e423

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours

24 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Combine and conquer: challenges for targeted therapy combinations in early phase trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Clinical radioimmunotherapy--the role of radiobiology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Adjuvant Intraarterial Lipiodol or ¹³¹I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Five years of molecular radiotherapy growth in the UK: survey results from 2007 to 2012.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Advances in anticancer radiopharmaceuticals.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Survival of tumor and normal cells upon targeting with electron-emitting radionuclides

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

What is the Role of the Bystander Response in Radionuclide Therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

The concurrent chemoradiation paradigm--general principles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Sequelae and survivorship in patients treated with (131)I-MIBG therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Peptide-receptor radionuclide therapy for endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radiopeptides for Imaging and Therapy: A Radiant Future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Alpha-particles for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable li

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Targeting the DNA Damage Response in Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Integration of EGFR inhibitors with radiochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Trial Watch: Radioimmunotherapy for oncological indications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Improving external beam radiotherapy by combination with internal irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radiation enhancement of radiolabelled antibody deposition in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Radiobiology of systemic radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930379-0

7 January 2021

10.1016/S1470-2045(17)30379-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28677577%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference